Obeticholic Acid PCD Pharma Franchise Company
Cafoli Lifecare offers Obeticholic Acid as part of its specialty hepatology portfolio, with 2 formulations available in tablet form. Both are manufactured at WHO-GMP certified, DCGI-approved facilities and offered to PCD franchise partners with exclusive district-wise monopoly rights — a high-value addition for distributors working with gastroenterology and liver-care centres.
What is Obeticholic Acid?
Obeticholic Acid is a semi-synthetic bile acid analogue and a potent agonist of the farnesoid X receptor (FXR), a nuclear receptor that regulates bile acid synthesis, transport and secretion. By activating FXR it suppresses the synthesis of bile acids in the liver and promotes their clearance, reducing the hepatocellular injury caused by bile acid accumulation in cholestatic liver disease. It is used in primary biliary cholangitis, typically in combination with ursodeoxycholic acid in patients with an inadequate response to UDCA alone, or as monotherapy in those unable to tolerate it. Compound data is available on PubChem.
Available Obeticholic Acid Formulations
The Cafoli Lifecare Obeticholic Acid range currently comprises 2 formulations, available in the following dosage form:
Brand names, compositions, pack sizes and net rates are shared with registered franchise enquiries. Contact our team for the current Obeticholic Acid price list.
Therapeutic Applications of Obeticholic Acid
Prescribed under specialist supervision for:
- Primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid, where the response to UDCA alone is inadequate
- Primary biliary cholangitis as monotherapy in adults intolerant of ursodeoxycholic acid
Prescriber specialties: hepatologists and gastroenterologists, predominantly at tertiary care and liver-specialty centres.
Safety note: Obeticholic Acid is a prescription-only specialty medicine. Dosing must be adjusted according to hepatic impairment, and treatment requires ongoing monitoring of liver function, as serious liver injury has been reported with incorrect dosing in patients with advanced cirrhosis. It must be initiated and supervised by a specialist.
Why Obeticholic Acid is a High-Potential Molecule for Distributors
Obeticholic Acid is the opposite of a volume play, and that is precisely its appeal. Primary biliary cholangitis is a rare, chronic, progressive autoimmune liver disease with no cure — patients stay on therapy indefinitely, so once a prescription is initiated it repeats month after month for years. Specialty hepatology products carry high per-pack values and, critically, are not subject to the counter-level substitution and price erosion that destroys margins in general medicine, because the chemist simply cannot swap a specialist's PBC prescription. Diagnosis rates for PBC in India are also rising as liver clinics and autoimmune serology become more widely available, so the addressable patient pool is expanding. For a franchise partner, this is a low-inventory, high-value SKU that establishes credibility with hepatology centres — the very accounts that drive the rest of a liver-care and gastro portfolio.
Why Choose Cafoli Lifecare
- Monopoly rights — exclusive district-wise marketing rights for the Obeticholic Acid range
- WHO-GMP certified manufacturing and DCGI-approved products
- Promotional inputs — visual aids, MR bags, prescription pads, samples and reminder cards
- 1000+ franchise partners across India with an on-time dispatch record
- Transparent net rates and dedicated franchise support
References
- PubChem — Obeticholic Acid compound record
- PubMed — Obeticholic Acid in primary biliary cholangitis
- MedlinePlus — Drugs, Herbs and Supplements
Our formulations of Obeticholic Acid find application in many critical therapeutic areas. Its therapeutic spectrum includes, but is not limited to: